Floatz logo

Zagociguat

MELAS Syndrome

Tisento TherapeuticsSmall moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the MELAS Syndrome cohort.

Asset / SponsorPhaseRating
Sonlicromanol
Khondrion BV
Phase 3BB
Fluzone
Stanford University
Phase 4BB
Idebenone
Michio Hirano
Phase 2B
ARG
The Hospital for Sick Children
Phase 2B
Tti-0102
Thiogenesis Therapeutics, Inc.
Phase 2CCC

View all 10 →

Same molecule, other indications

Zagociguat is also rated in:

Alzheimer diseaseActive
CCC
Indicative · Phase 2
53 / 100
View asset →
schizophreniaActive
CC
Indicative · Phase 1
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →